Last week, Sanofi SA (NASDAQ:SNY) said it is negotiating with Clayton Dubilier & Rice (CD&R) to potentially sell a 50% controlling stake in Opella, its consumer healthcare business.
The deal could be valued at about 15 billion euros ($16.4 billion), making it one of the largest European transactions this year. Sanofi is likely to retain a minority stake in the Opella business.
France’s government has hinted at the possibility of blocking the sale of Sanofi’s consumer pharmaceuticals division to CD&R, citing concerns over employment and national healthcare interests.
Also Read: GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report.
Citing French industry minister Marc Ferracci, ...
